Literature DB >> 8994897

Clinical global impressions in Alzheimer's clinical trials.

L S Schneider1, J T Olin.   

Abstract

This article reviews the history of Clinical Global Impressions of Change (CGIC) instruments, their use and limitations in clinical trials of Alzheimer's disease, and the development of the National Institute on Aging's Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale (ADCS-CGIC). Originally, CGICs were simple and unstructured instruments that asked a clinician to rate change over the duration of a clinical trial. The method, however, failed to consistently detect treatment effects, leading to the development of more structured and subsequently validated approaches, such as the Clinician Interview-Based Impression Scale (CIBI) and the ADCS-CGIC. Both are currently used in clinical trials. The implications and importance of choosing an appropriate global rating are discussed.

Entities:  

Mesh:

Year:  1996        PMID: 8994897     DOI: 10.1017/s1041610296002645

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  20 in total

Review 1.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 2.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

3.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

Review 4.  The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.

Authors:  Barry Reisberg; Isabel Monteiro; Carol Torossian; Stefanie Auer; Melanie B Shulman; Santosh Ghimire; Istvan Boksay; Francoise Guillo BenArous; Ricardo Osorio; Aninditha Vengassery; Sheema Imran; Hussam Shaker; Sadaf Noor; Shazia Naqvi; Sunnie Kenowsky; Jinfeng Xu
Journal:  Dement Geriatr Cogn Disord       Date:  2014-04-07       Impact factor: 2.959

Review 5.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

Authors:  D P Devanand; Jacobo Mintzer; Susan Schultz; David Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Howard Andrews; Bruce Levin
Journal:  Am J Geriatr Psychiatry       Date:  2012-04       Impact factor: 4.105

7.  Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

Authors:  Andreas Wentrup; Wolfgang H Oertel; Richard Dodel
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

8.  Daytime sleepiness in elderly Parkinson's disease patients and treatment with the psychostimulant modafinil: A preliminary study.

Authors:  Johan Lökk
Journal:  Neuropsychiatr Dis Treat       Date:  2010-04-07       Impact factor: 2.570

9.  Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

Authors:  P S Aisen
Journal:  J Prev Alzheimers Dis       Date:  2015

10.  The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial.

Authors:  Sarah A Morrow; Tanya Kaushik; Peter Zarevics; David Erlanger; Mark F Bear; Frederick E Munschauer; Ralph H B Benedict
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.